Anti-Angiogenesis Drug Discovery and Development

Mostrar otras versiones (3)

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inh...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Atta-ur-Rahman
Otros Autores: Choudhary, M. Iqbal
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Singapore : Bentham Science Publishers, 2020.
Colección:Anti-Angiogenesis Drug Discovery and Development Ser.
Temas:
Neovascularization inhibitors.
Neovascularization.
Drug development.
Angiogenesis Inhibitors
Neovascularization, Pathologic
Néovascularisation > Inhibiteurs.
Néovascularisation.
Médicaments > Développement.
Drug development
Neovascularization
Neovascularization inhibitors
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover
  • Title
  • Copyright
  • End User License Agreement
  • Contents
  • Preface
  • List of Contributors
  • Therapeutic Targeting of the Tumor Vasculature: Past, Present and Future
  • Peace Mabeta1,*, Mike Sathekge2 and Vanessa Steenkamp3
  • INTRODUCTION
  • ANGIOGENESIS IN TUMOR PROGRESSION
  • The Tumor Vasculature
  • Importance of Vascular Endothelial Growth Factor Signaling in Cancer
  • Therapeutic Targeting of Vascular Endothelial Growth Factor
  • BEYOND BEVACIZUMAB
  • Ramucirumab
  • Apatinib
  • Effectiveness of Anti-VEGF Versus Anti-VEGFR Therapy
  • DEVELOPMENT OF RESISTANCE TO VEGF/VEGFR-2 TARGETING DRUGS
  • Platelet-Derived Growth Factor Pathway
  • Fibroblast Growth Factor Signaling in Anti-Cancer Therapy
  • Angiopoietin-Tie Pathway in Therapeutic Anti-Angiogenesis
  • THERAPEUTIC TARGETING OF MULTIPLE ANGIOGENIC PATHWAYS
  • Multi-Targeting Tyrosine Kinase Inhibitors
  • Sorafenib
  • Sunitinib
  • Axitinib
  • Pazopanib
  • Nintedanib
  • Multi-Targeting Versus Mono-Targeting AIs
  • FUSION PEPTIDES AND DECOY RECEPTORS
  • Aflibercept
  • Abexinostat and Panobinostat Attenuate Hypoxia
  • IMMUNE CELLS AND THE EFFECTIVENESS OF ANGIOGENESIS INHIBITORS
  • OVERCOMING INFLAMMATION
  • ANGIOGENESIS INHIBITORS AND IMMUNOTHERAPY
  • Normalization of the Tumor Vasculature
  • FUTURE PERSPECTIVE
  • IMAGING BIOMARKERS IN ANGIOGENESIS
  • CONCLUSION
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Anti-angiogenic Mechanism, Biochemical Factors' Roles, Therapeutic Agents, and Under Clinical Trial Drugs for Breast and Prostate Cancers
  • Varsha M. Singh1, Shilpa J. Newati1, Mohammad Yusuf2, Alexandre Bridoux3,4, Salman A. A. Mohammed5, Naseem Akhtar6 and Riaz A. Khan1,5,*
  • INTRODUCTION: THE ANGIOGENESIS AND CANCERS
  • ANGIOGENIC BIOMECHANISMS: NORMAL VERSUS TUMOR-INDUCED
  • Tumor Vasculature
  • Operational Signaling Pathways in Tumor
  • Angiogenic Promoters and their Involvement in Breast Cancer
  • Angiogenin
  • Vascular Endothelial Growth Factors (VEGFs)
  • Interleukins
  • Fibroblast Growth Factors (FGF)
  • Matrix MetalloProteinases (MMPs) and Matrix Remodeling
  • Angiopoietins
  • Roles of Integrins in Tumorigenesis
  • ANGIOGENIC INHIBITORS
  • Interferons
  • Endostatin
  • Angiostatin
  • Thrombospondin
  • Decorin
  • Commercially Aailable Angiogenic Inhibitors
  • CLINICAL TRIALS TOWARDS ANTI-ANGIOGENIC DRUGS DEVELOPMENT
  • Bevacizumab
  • Cilengitide
  • Aflibercept
  • Ramucirumab
  • Sorafenib
  • Sunitinib
  • Vandetanib
  • Axitinib
  • Pazopanib
  • Drugs Approved to Treat Breast Cancers
  • RELATIONSHIP BETWEEN INFLAMMATION, ANGIOGENESIS, AND COAGULATION IN PROSTATE CANCERS
  • ANGIOGENESIS, THROMBOSIS AND INFLAMMATION MEDIATORS' CROSSTALK
  • 6.1. Angiogenesis and Inflammation Mediators' Crosstalk
  • Angiogenic Capability of Tumors and Thromboembolic Crosstalk
  • CLINICAL TRIALS FOR ANTI-ANGIOGENIC PROSTATE CANCER DRUG DEVELOPMENT

Ejemplares similares